Talphera (TLPH) Non-Current Assets (2010 - 2026)
Talphera's (TLPH) quarterly Non-Current Assets came in at $8.8 million in Q1 2026, little changed year-on-year from $8.8 million in Q1 2025, and little changed quarter-over-quarter from $8.8 million in Q4 2025.
Talphera (TLPH) Non-Current Assets (2010 - 2026) Analysis & Trends
Talphera's Non-Current Assets history runs 17 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- On a quarterly basis, Non-Current Assets changed 0.0% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $35.3 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $8.8 million, changed 0.0% from the prior year.
- Non-Current Assets steadied at $8.8 million in Q1 2026 per TLPH's latest filing, from $8.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.2 million in Q1 2022 and bottomed at $8.8 million in Q4 2023.
- The 5-year median for Non-Current Assets is $8.8 million (2023), against an average of $12.6 million.
- Across the five-year window, Non-Current Assets soared 81.89% in 2022 and tumbled 69.35% in 2023, its largest moves.
- Year by year, Non-Current Assets stood at $22.9 million in 2022, then slumped by 61.52% to $8.8 million in 2023, then changed by 0.0% to $8.8 million in 2024, then changed by 0.0% to $8.8 million in 2025, then changed by 0.0% to $8.8 million in 2026.
- Per Business Quant, the three latest TLPH Non-Current Assets figures stand at $8.8 million (Q1 2026), $8.8 million (Q4 2025), and $8.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 8.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.82 Mn |
| Dec 31, 2025 | 8.82 Mn |
| Sep 30, 2025 | 8.82 Mn |
| Jun 30, 2025 | 8.82 Mn |
| Mar 31, 2025 | 8.82 Mn |
| Dec 31, 2024 | 8.82 Mn |
| Sep 30, 2024 | 8.82 Mn |
| Jun 30, 2024 | 8.82 Mn |
| Mar 31, 2024 | 8.82 Mn |
| Dec 31, 2023 | 8.82 Mn |
| Sep 30, 2023 | 8.84 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Mar 31, 2023 | 8.94 Mn |
| Dec 31, 2022 | 22.92 Mn |
| Sep 30, 2022 | 23.77 Mn |
| Jun 30, 2022 | 24.14 Mn |
| Mar 31, 2022 | 29.16 Mn |
| Dec 31, 2021 | 27.40 Mn |
| Sep 30, 2021 | 20.51 Mn |
| Jun 30, 2021 | 20.62 Mn |